{"prompt": "['Determination of Sample Size', 'A sample size of approximately 200 patients is planned for this study.', 'For the purpose of the sample size calculation, the incidence of adverse events was chosen as the', 'safety endpoint of primary interest.', 'If the observed incidence of adverse events is between 2.5% and 15%, the precision for the estimated', 'incidence rate is presented below according to the 95% Clopper-Pearson Cls (Table 2).', 'Emicizumab - F. Hoffmann-La Roche Ltd', '83 / Protocol MO39129, Version 3']['Table 2', 'Clopper-Pearson 95% Cls for the Incidence of AEs (Based on N=200)', 'Number of AE Events', '(Observed AE Incidence)', '95% Clopper-Pearson Cls', '5 (2.5%)', '0.8%-5.7%', '10 (5.0%)', '2.4%-9.0%', '20 (10.0%)', '6.2%-15.0%', '30 (15.0%)', '10.4%-20.7%', 'AE=adverse event, Cl=confidence interval', 'Interim Analyses', 'The first interim analysis will be performed once approximately 100 patients have received treatment', 'with emicizumab for at least 24 weeks. A second interim analysis will be performed when', 'approximately 100 patients have received treatment with emicizumab for at least 52 weeks. The data', 'from these analyses will subsequently be presented to an iDMC in order to enable them to effectively', 'monitor the study.', 'Details regarding the planned interim analyses will be provided in the SAP and iDMC charter.', 'Emicizumab - F. Hoffmann-La Roche Ltd', '84 / Protocol MO39129, Version 3']['LIST OF ABBREVIATIONS AND DEFINITIONS OF TERMS', 'Abbreviation', 'Definition', 'ABR', 'annualized bleeding rate', 'ADA', 'anti-drug antibody', 'ALT', 'alanine aminotransferase', 'aPCC', 'activated prothrombin complex concentrate', 'aPTT', 'activated partial thromboplastin time', 'AST', 'aspartate aminotransferase', 'AUC', 'area under the curve', 'AUCT', 'area under the curve during the dosage interval', 'BU', 'Bethesda unit', 'BUN', 'blood urea nitrogen', 'CI', 'confidence interval', 'Cmax', 'maximum plasma concentration', 'CONSORT', 'Consolidated Standards of Reporting Trials', 'CRO', 'contract research organization', 'Ctrough', 'concentration at the end of the dosage interval', 'CTX', 'C-terminal telopeptide of collagen 1', 'CVAD', 'central venous access device', 'CWA', 'clot waveform analysis', 'cyFcyR', 'cynomolgus monkey Fcy receptor', 'EC', 'Ethics Committee', 'ECG', 'electrocardiogram', 'ECL', 'electrochemiluminescence', 'eCRF', 'electronic Case Report Form', 'EDC', 'electronic data capture', 'EDTA', 'ethylenediaminetetraacetic acid', 'ELISA', 'enzyme linked immunosorbent assay', 'ePRO', 'electronic patient-reported outcome', 'EQ-5D-5L', 'EuroQoL Five-Dimension-Five Levels Questionnaire', 'EQ-VAS', 'EuroQoL visual analogue scale', 'E.U.', 'European Union', 'FDA', 'Food and Drug Administration', 'FEIBA', 'Factor eight inhibitor bypassing activity', 'FIX', 'Factor IX', 'FIXa', 'activated Factor IX', 'FIX:Ag', 'Factor IX antigen', 'FVIIa', 'activated Factor VII', 'Emicizumab - F. Hoffmann-La Roche Ltd', '85 / Protocol MO39129, Version 3']\n\n###\n\n", "completion": "END"}